Vadim Backman,
Walter Dill Scott Professor of Biomedical Engineering,
Northwestern University
Dr. Vadim Backman is the Walter Dill Scott Professor of Biomedical Engineering at the McCormick School of Engineering and Applied Sciences, Northwestern University and Program Leader in Cancer Bioengineering, Nanotechnology and Chemistry at the Robert H. Lurie Comprehensive Cancer Institute, and the CEO of NanoCytomics, LLC. He received a Ph.D. in Medical Engineering from Harvard University and the Massachusetts Institute of Technology. Dr. Backman’s research is focused on bridging advances in biomedical optics into biomedical research and clinical medicine. He develops novel optics technologies for the characterization and imaging of biological tissue with a focus on the nanoscale, microscale and molecular levels. His research spans from technology development to large scale clinical validation. Dr. Backman has received numerous awards including being selected as one of the top 100 young innovators in the world by Technology Review Magazine and the National Science Foundation CAREER award.
Transforming Cancer Risk Screening in Primary Care Setting
Friday, 19 September 2014 at 14:00
Add to Calendar ▼2014-09-19 14:00:002014-09-19 15:00:00Europe/LondonTransforming Cancer Risk Screening in Primary Care SettingPoint-of-Care Diagnostics World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
NanoCytomics is developing a new optical technology platform termed nanocytology for highly sensitive, cost-effective and non-invasive cancer screening of populations in a primary care setting by means of the measurement of the nanoscale architecture of biological cells. Nanocytology-detectable alterations in chromatin nanoarchitecture are a highly robust and accurate marker of field carcinogenesis in clinical trials in lung, colon, prostate, pancreatic, esophageal, ovarian and thyroid cancers. A significant application of nanocytology is in cancer screening enabled by the detection of field carcinogenesis via the analysis of the nanoarchitecture of cells obtained from easily accessible surrogate tissue sites, with the objective to increase the detection rate of significant pre-neoplastic or neoplastic lesions while reducing overdiagnosis. Examples include the analysis of rectal cells for colon neoplasia and buccal (cheek) cells for lung cancer identification. Data from multi-institutional clinical trials has demonstrated that nanocytology has the potential to become a new platform for cancer screening broadly applicable to a number of organ sites from which cellular specimens can be obtained.
Add to Calendar ▼2014-09-18 00:00:002014-09-19 00:00:00Europe/LondonPoint-of-Care Diagnostics World CongressPoint-of-Care Diagnostics World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2014-09-19 14:00:002014-09-19 15:00:00Europe/LondonTransforming Cancer Risk Screening in Primary Care SettingPoint-of-Care Diagnostics World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
